Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3981354 | 0.85 | ALDH1A1 (0.50) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL4363143 | 0.83 | POLB (0.51) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17596059 | 0.81 | NPC1 (0.47) | MAPK1SMN1; SMN2ALDH1A1POLBTP53 | |
| SCHEMBL4360943 | 0.80 | PDE4B (0.49) | MAPK1POLBTP53CYP1A2CYP3A4 | |
| SCHEMBL4373383 | 0.80 | PDE4B (0.55) | MEN1KMT2AMAPK1ALDH1A1LMNA | |
| SCHEMBL5539532 | 0.80 | TP53 (0.55) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17338678 | 0.78 | CHRM5 (0.46) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL503999 | 0.78 | KDM4E (0.64) | MEN1KMT2AALDH1A1LMNATP53 | |
| SCHEMBL5782319 | 0.77 | PPARG (0.46) | MEN1KMT2AMAPK1ALDH1A1LMNA | |
| SCHEMBL5539525 | 0.77 | TP53 (0.52) | MEN1KMT2AMAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441719-B1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-7803819-B2 | DPP IV inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-09-28 | — | — | US | disclosed |
| CN-1713907-B | N-substituted pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| CN-101031540-B | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN LA ROCHE | 2010-05-26 | — | — | CN | disclosed |
| CN-100577660-C | N-substituted-1H-indol-5-propionic acid compounds as PPAR agonists used for the treatment of diabetes | HOFFMANN LA ROCHE | 2010-01-06 | — | — | CN | disclosed |
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1567523-B1 | INDOLYL DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-08-20 | — | — | EP | disclosed |
| US-7314884-B2 | non-insulin dependent diabetes mellitus, and impaired glucose tolerance; dipeptidyl peptidase IV (DPP-IV) inhibitors eg (2S)-1-{[(1S)-2-(5-cyano-2-methyl-indol-1-yl)-1-methyl-ethylamino]-acetyl}-pyrrolidine-2-carbonitrile | HOFFMANN-LA ROCHE INC. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070259925-A1 | DPP IV INHIBITORS | BOEHRINGER MARKUS | 2007-11-08 | — | — | US | disclosed |
| WO-2004048371-A1 | INDOLYL DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-20040106657-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-03 | — | — | US | disclosed |
| WO-2004024726-A1 | N-SUBSTITUTED-1H-INDOL-5-PROPIONIC ACID COMPOUNDS AS PPAR AGONISTS USEFUL FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-25 | — | — | WO | disclosed |
| US-20040053979-A1 | Indolyl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1392295-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. Hoffmann-La Roche AG (CH) | 2004-03-03 | — | — | EP | disclosed |
| US-6642389-B2 | For therapy of diabetes | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030130281-A1 | DPP IV inhibitors | HOFFMAN-LA ROCHE INC. | 2003-07-10 | — | — | US | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |
| US-20030055265-A1 | Oxazole derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2002092084-A1 | CARBOXYLIC ACID SUBSTITUTED OXAZOLE DERIVATIVES FOR USE AS PPAR-ALPHA AND -GAMMA ACTIVATORS IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106657-A1 | Indolyl derivatives | GPR119, IRS1, INSR | MEN1 760/4885KMT2A 2935/4885MAPK1 1025/4885 |
| US-20040053979-A1 | Indolyl derivatives | UGT1A8, CYP2C8, UGT1A1 | MEN1 1022/4885KMT2A 2299/4885MAPK1 2463/4885 |
| US-20070259925-A1 | DPP IV INHIBITORS | DPP4, DPP3, DPP7 | MEN1 3856/4885KMT2A 2992/4885MAPK1 1364/4885 |
| US-20030055265-A1 | Oxazole derivatives | PPARD, PPARA, PPARG | MEN1 4859/4885KMT2A 4142/4885MAPK1 1795/4885 |
| US-20030130281-A1 | DPP IV inhibitors | DPP4, DPP3, DPP7 | MEN1 3537/4885KMT2A 2888/4885MAPK1 513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.